OPTIRAY 300 Rx
Generic Name and Formulations:
Ioversol 636mg/mL; soln for intravascular administration; contains organically bound iodine 300mg per mL.
Indications for OPTIRAY 300:
Cerebral angiography and peripheral arteriography. For contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography.
Individualize. Visualization of carotid or vertebral arteries: 2–12mL, repeat as necessary. Aortic arch inj for simultaneous four vessel study: 20–50mL; total procedure doses should not exceed 200mL. Peripheral arteriography: Aortic-iliac runoff: 60mL (range 20–90mL); Common iliac, femoral: 40mL (range 10–50mL); Subclavian, brachial: 20mL (15–30mL); total procedure doses should not exceed 250mL. Venography: 50–100mL per extremity; max 250mL. Head imaging: 50–150mL; max 150mL. Body imaging: Bolus inj: 25–75mL; Infusion: 50-150mL; max 150mL. IV urography: 50–75mL; may use higher dose of 1.6mL/kg (max 150mL) for optimum results.
See full labeling. Not for intrathecal use. Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Risk of serious thromboembolic events (eg, MI, stroke), neurologic sequelae, including paralysis. Suspected thrombosis, phlebitis, severe ischemic disease, local infection: caution in venography. Advanced arteriosclerosis, severe hypertension, cardiac decompensation, senility, recent cerebral thrombosis/embolism, and migraine: use extreme caution in cerebral arteriography. Avoid angiography with homocystinuria. Renal or hepatic impairment. Anuria. CHF. Pulmonary hypertension. Chronic pulmonary emphysema. Dehydration. Multiple myeloma or other paraproteinemia. Homozygous sickle cell disease. Pheochromocytoma. Thyroid disorder. Diabetes. Myasthenia gravis. Anesthetized patients. Monitor blood pressure and ECG. Maintain adequate hydration. Avoid extravasation. Elderly. Pregnancy (Cat.B). Nursing mothers.
Patients with hepatic or biliary disorder that have received cholecystographic agents recently; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Radiopaque contrast agent.
Nausea, headache, hypersensitivity; cardiovascular, CNS, respiratory, skin reactions, endocrine, others (see full labeling).
OPTIRAY 240: Bottles (50mL)—25, 100mL—12, 150mL—12, 200mL—12, Syringes (50mL, 125mL)—20, RFID-Tagged syringes (125ml)—20; OPTIRAY 300: Bottles (50mL—25, 100mL—12, 150mL—12, 200mL—12, Syringes (50mL, 100mL, 125mL)—20, RFID-Tagged syringes (100mL, 125mL)—20; OPTIRAY 320: Vials (20mL, 30mL)—25, Bottles (50mL)—25, 75mL, 100mL, 150mL, 200mL—12, Syringes (30mL, 50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (50mL, 75mL, 100mL, 125mL)—20; OPTIRAY 350: Bottles (50mL)—25, 75mL, 100mL, 150mL, 200mL—12, Syringes (50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (50mL, 75mL, 100mL, 125mL)—20
Clinical Pain Advisor Articles
- Brain Plasticity in Patients With Complex Regional Pain Syndrome
- Chronic Pain Associated With Traumatic Brain Injury: Causes and Management
- Perturbation-Based Rehabilitation Effective for Chronic Low Back Pain
- Migraine Frequency Correlated With Depression and Anxiety
- IBS-Associated Chronic Pain: Formulation of Core Diagnostic Criteria
- Cannabis Use Associated With Aberrant Drug Behaviors
- Walgreens to Carry Naloxone in All Pharmacies to Combat Drug Abuse
- Independent Pharmacies Expanding Services Available to Patients
- Ketamine Exhibits Effective Pain Relief for Refractory Headaches
- Pain In Elite Athletes: IOC Recommendations on Contributing Factors and Treatment Approach
- Naproxen Plus Muscle Relaxants vs Naproxen Monotherapy for Low Back Pain
- Pain Processing: Examining the Role of Oxytocin
- Short- vs Long-Acting Opioids for Osteoarthritis Pain
- Extended-Release Naltrexone Injections Reduce Opioid Dependence
- Depressive Symptoms in Medical Interns Increased With Work-Family Conflicts